| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOCS2 |
| Uniprot No | O14508 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MTLRCLEPSGNGGEGTRSQWGTAGSAEEPSPQAARLAKALRELGQTGWYW GSMTVNEAKEKLKEAPEGTFLIRDSSHSDYLLTISVKTSAGPTNLRIEYQ DGKFRLDSIICVKSKLKQFDSVVHLIDYYVQMCKDKRTGPEAPRNGTVHL YLTKPLYTSAPSLQHLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQV |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SOCS2重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*"Structural and functional characterization of the SOCS2-elongin C-elongin B complex"*
**作者**：Bullock AN, et al.
**摘要**：该研究通过X射线晶体学解析了SOCS2蛋白与Elongin B/C复合物的三维结构，揭示了SOCS2如何通过SH2结构域特异性识别生长激素受体(GHR)磷酸化位点，并阐明了其在泛素连接酶复合体中的调控机制。
2. **文献名称**：*"SOCS2 negatively regulates growth hormone signaling in vitro and in vivo"*
**作者**：Greenhalgh CJ, et al.
**摘要**：通过表达重组SOCS2蛋白，研究证实其通过结合生长激素受体(GHR)和抑制JAK2激酶活性，负调控生长激素信号通路，并发现SOCS2基因敲除小鼠出现生长过度表型。
3. **文献名称**：*"Recombinant SOCS2 protein attenuates inflammatory responses via inhibition of NF-κB activation in macrophages"*
**作者**：Li Y, et al.
**摘要**：研究利用大肠杆菌表达系统制备重组SOCS2蛋白，证明其可通过抑制TLR4介导的NF-κB信号通路，减少巨噬细胞中促炎细胞因子(如TNF-α、IL-6)的释放，提示其潜在抗炎治疗价值。
---
以上文献涵盖SOCS2的结构解析、信号调控机制及治疗应用方向，均涉及重组蛋白的实验分析。如需具体发表年份或期刊，可进一步补充检索。
SOCS2 (Suppressor of Cytokine Signaling 2) is a member of the SOCS family, a group of intracellular proteins that negatively regulate cytokine signaling pathways, particularly those mediated by the JAK-STAT (Janus kinase–signal transducer and activator of transcription) cascade. Discovered in the late 1990s, SOCS2 plays a critical role in maintaining immune homeostasis, cell growth, and differentiation by inhibiting excessive cytokine responses. Structurally, it contains a central SH2 (Src homology 2) domain for binding phosphorylated tyrosine residues on cytokine receptors or associated kinases, a variable N-terminal region, and a C-terminal SOCS box that recruits E3 ubiquitin ligase complexes to target proteins for proteasomal degradation.
SOCS2 is unique in its dual regulatory capacity, acting as both a suppressor and a facilitator of signaling depending on cellular context. It is prominently involved in growth hormone (GH) and insulin-like growth factor (IGF-1) signaling, influencing body growth, metabolism, and tissue development. Dysregulation of SOCS2 has been linked to pathologies such as cancer, inflammatory disorders, and metabolic syndromes. For instance, its overexpression in certain tumors may promote cell proliferation, while deficiencies are associated with hypersensitivity to cytokines and autoimmune conditions.
Recombinant SOCS2 protein, produced via bacterial or mammalian expression systems, is widely used in biomedical research to study molecular interactions, signaling mechanisms, and therapeutic potential. Its applications include in vitro binding assays, structural studies, and screening for inhibitors or modulators of cytokine pathways. By mimicking or blocking endogenous SOCS2 activity, this recombinant tool aids in deciphering its complex roles in health and disease, offering insights for drug development targeting immune dysregulation or oncogenic signaling.
×
